EBV-associated mononucleosis leads to long-term global deficit in T cell responsiveness to IL-15.

Lack of IL-15Rα expression post-mononucleosis.

Sauce Delphine1,2, Larsen Martin1,2, Curnow S John2, Leese Alison M.1,2, Moss Paul AH.1,2, Hislop Andrew D.1,2, Salmon Michael2, Rickinson Alan B.1,2.

1. CRUK Institute for Cancer Studies, University of Birmingham, Birmingham, UK.
2. MRC Centre for Immune Regulation, University of Birmingham, Birmingham, UK.

Corresponding author: A. B. Rickinson
CRUK Institute for Cancer Studies
University of Birmingham
Vincent Drive, Edgbaston
Birmingham B15 2TT
UK
Tel: +44 121 414 4492
Fax: +44 121 414 4486
E-mail: A.B.Rickinson@bham.ac.uk

The authors have no conflicting financial interests.

This study was supported by the Medical Research Council, United Kingdom. Delphine Sauce has benefited from the Lavoisier grant from the Ministère des affaires étrangères, France.
Abstract

In mice the interleukins (IL) 7 and 15 are involved in T cell homeostasis and the maintenance of immunologic memory. Here we follow virus-induced responses in infectious mononucleosis (IM) patients from primary Epstein-Barr virus (EBV) infection into long-term virus carriage, monitoring IL-7 and IL-15 receptor (IL-R) expression by antibody staining and cytokine responsiveness by STAT5 phosphorylation and \textit{in vitro} proliferation. Expression of IL-7R\(\alpha\) was lost from all CD8\(^+\) T cells, including EBV epitope-specific populations, during acute IM. Thereafter expression recovered quickly on total CD8\(^+\) cells but slowly and incompletely on EBV-specific memory cells. Expression of IL-15R\(\alpha\) was also lost in acute IM and remained undetectable thereafter not just on EBV-specific CD8\(^+\) populations but on the whole peripheral T and NK cell pool. This deficit, correlating with defective IL-15 responsiveness \textit{in vitro}, was consistently observed in patients up to 14 years post-IM but not in patients after cytomegalovirus (CMV)-associated mononucleosis, nor in healthy EBV carriers with no history of IM, nor in EBV-naïve individuals. By permanently scarring the immune system, symptomatic primary EBV infection provides a unique cohort of patients through which to study the effects of impaired IL-15 signalling on human lymphocyte functions \textit{in vitro} and \textit{in vivo}. 
Introduction

The immune system relies on tightly controlled mechanisms to regulate the size of lymphocyte pools. From work in mouse systems, cytokines of the common \( \gamma \) chain (\( \gamma_c \)) family appear to play an important role in T cell homeostasis\(^1\). In particular, interleukin (IL)-7 is required for the maintenance and homeostatic proliferation of both naïve and memory T cells\(^2,3\) and is thought to act principally through up-regulation of anti-apoptotic proteins. In parallel, IL-15 is involved in the generation and homeostatic (antigen-independent) maintenance of memory CD8\(^+\) T cells through acting as a growth, and possibly also as an anti-apoptotic, factor\(^4-6\). T cell responsiveness to these cytokines is in each case determined by expression of the relevant receptor on the cell surface. The IL-7 receptor is a heterodimer consisting of an \( \alpha \) chain (CD127) that binds IL-7 with high-affinity (\( K_a = 10^{-10} \) M) and the common \( \gamma_c \) (CD132). By contrast, the IL-15 receptor involves a private \( \alpha \) chain, a \( \beta \) subunit (CD122) shared with the IL-2 receptor, and the common \( \gamma_c \). The \( \alpha \) chain alone binds to IL-15 with high affinity (\( K_a = 10^{-11} \) M) and in this case the \( \beta/\gamma_c \) complex alone can also bind the cytokine, albeit with much lower affinity\(^7\). Both the IL-7 and IL-15 receptors signal via janus kinase (JAK) family members; in both cases, the \( \alpha \) chain signals via JAK1 and the \( \gamma_c \) via JAK3, leading to the nuclear translocation of STAT3 and STAT5 respectively\(^8\).

Of particular interest is the role which these cytokines may also play in the regulation of antigen-dependent responses. In mouse models, this is best studied in the context of CD8\(^+\) T cell responses induced by viral infection. Thus, IL-15-deficient mice show reductions in the initial expansion of effector CD8\(^+\) T cells that typify
acute viral infection\textsuperscript{9,10}, implying a role for this cytokine in the generation and proliferation of reactive cells. IL-15Rα expression is indeed reported to be enhanced on recently activated mouse CD8+ T cells\textsuperscript{4,10}. By contrast, expression of the IL-7Rα is down-regulated on most if not all activated cells during acute primary infection\textsuperscript{11,12}. Interestingly, however, this receptor is either retained or re-expressed on a small subset (5-10\%) of the expanded effector population and these cells go on to up-regulate bcl-2, thereby escaping apoptosis and allowing their selection into long-term memory\textsuperscript{4,11,13}. Thus, in mice, both IL-7 and IL-15 appear to be playing important complementary roles at different stages of the T cell response to infection with intracellular pathogens\textsuperscript{4,12,14}.

Here we have used the model of Epstein-Barr virus (EBV) infection to ask to what extent the above findings mirror events occurring during the human T cell response to viral challenge. Primary EBV infection, as seen in infectious mononucleosis (IM) patients, is associated with a marked CD8+ T cell expansion that is largely virus-specific and has been well characterised in terms of immunodominant EBV lytic and latent cycle epitopes\textsuperscript{15,16}. We therefore followed IM patients prospectively, from the time of acute IM through convalescence into the asymptomatic virus carrier state, and characterized both EBV-specific and total T cell population for cytokine receptor expression and for cytokine responsiveness.
Methods

Donors

Cases of IM were identified on clinical grounds and confirmed by high leukocyte counts. EBV-associated cases were identified by heterophile antibody-positivity and high EBV DNA loads in peripheral blood mononuclear cells (PBMCs). Cytomegalovirus (CMV)-associated cases were identified among heterophile antibody-negative adult mononucleosis patients by the presence of CMV-specific IgM antibodies, with subsequent isotype switching to IgG, and high CMV DNA loads in plasma. Individual IM patients were bled in the acute phase and/or at different time points post-infection (between 1 month and 14 years); all patients included in the study had shown resolution of acute disease symptoms within 4 weeks of the initial acute phase. Blood samples were also taken from healthy donors, most of whom were in the same age range (18-30 yrs) as the EBV-IM patients. These included 30 individuals known to have been EBV and/or CMV carriers for at least 5 years and to have no prior history of IM, 30 individuals with no serological evidence of prior EBV infection, and 5 individuals with no serological evidence of prior CMV infection. In each case, PBMCs were isolated from heparinized blood and aliquots of cells cryopreserved. Approval was obtained from the South Birmingham Health Authority Local Research Ethics Committee for these studies. Informed consent was provided according to the Declaration of Helsinki.

Tetramers

HLA class I tetramers were prepared for the following epitopes/HLA combinations identified in earlier work: EBV lytic cycle epitopes: GLCTLVAML/HLA-
A*0201, YVLDHLIVV/HLA-A*0201, RAKFKQLL/HLA-B*0801, EPAQPQLTAY/HLA-B*3501; EBV latent cycle epitopes: CLGGLLTVM/HLA-A*0201, FLRGRAYGL/HLA-B*0801, QAKWRLQTL/HLA-B*0801, YPLHEQHGM/HLA-B*3501, HPVGEADYF/HLA-B*3501; CMV epitopes: NLVPMVATV/HLA-A*0201, VLEETSVML/HLA-A*0201, ELRRKMMYM/HLA-B*0801, ELKRKMIYM/HLA-B*0801, QIKVRVDMV/HLA-B*0801, IPSINVHHY/HLA-B*3501, TPRVTGGGAM/HLA-B*0701. Throughout this paper, the nomenclature for the epitopes has been abbreviated to the first three amino acids (underlined above). Peptides were purchased from Alta Biosciences (University of Birmingham, UK) and phycoerythrin (PE)-conjugated tetramers produced as described.

**Cell staining**

In stainings that included tetramers, cells were first incubated with a pretitrated concentration of phycoerythrin (PE)-conjugated tetramer (~0.5 µg/ml) at 37°C for 15 min, then washed and all further steps were conducted on ice. Cells were exposed to human IL-7Rα-specific antibodies (see below) for 30 min, followed by the appropriate fluorescein isothiocyanate (FITC) secondary antibodies for another 30 min; cells were then blocked with mouse serum (Dako, Glostrup, Denmark) and finally stained with a Tricolour-labelled anti-human CD8 monoclonal antibody (mAb; Caltag Laboratories, Burlingame, CA) for 30 min. Staining was analysed on an Epics flow cytometer (Beckman Coulter, Fullerton, CA). Goat anti-human IL-7Rα antibody (R&D systems, Minneapolis, MN) was detected by FITC-conjugated swine anti-goat IgG antibody (Caltag Laboratories); mouse anti-human IL-15Rα (R&D systems clone 151307) was detected by FITC-conjugated goat anti-mouse IgG1 (Southern
Biotechnology Associates, Inc., Birmingham, AL). As control, a FITC-conjugated IgG1 mouse isotype control was used followed by the above FITC-conjugated secondary reagent.

In examining mononuclear cell subsets for receptor expression, PBMCs were first exposed to the above human IL-Rα- specific antibodies followed by a FITC-conjugated second step reagent as above, then washed and stained for 30 min on ice with either Tricolour-labelled CD8 or CD4-specific mAbs (Caltag Laboratories, Burlingame, CA) or PE-labelled CD56, CD19, CD14-specific mAbs (Immunotech, Marseille, France) and staining analysed as above. In confirmatory experiments (in combination with CD8 and CD4 stainings), we used a second IL-15Rα mAb (R&D systems clone 151303).

IL-7 and IL-15 -induced STAT5 phosphorylation

PBMCs were exposed to PE-labelled tetramer for 15 min at 37°C in the presence of recombinant IL-7 or IL-15 (R&D systems) at doses up to 100 ng/ml, then washed and fixed in 2% formaldehyde in phosphate-buffered saline (PBS; Gibco, Paisley, UK) for 10 min at room temperature. Cells were subsequently stained with Tricolour- labelled anti-CD8, then permeabilized with ice cold 90% methanol and stained intracellularly for 30 min at room temperature using rabbit anti-human phospho STAT5 mAb (Tyr694; Cell Signaling Technology, Beverly, MA) followed by FITC-conjugated goat anti- rabbit IgG (Southern Biotechnology Associates, Inc.) and analysed as above. In some cases, IL-15-induced STAT5 phosphorylation of total CD8+ T cells was assayed as above on PBMCs and in parallel on CD8+ purified T cells and CD14-depleted PBMCs from the same donors (Miltenyi Biotech, Bergisch Gladbach, Germany). CD8+ T cells were purified by positive selection (CD8 microbeads,
Miltenyi Biotech) and CD14+ cell depletion was performed using mAb-coated magnetic beads according to the manufacturer’s instructions (CD14 microbeads, Miltenyi Biotech).

**IL-7 and IL-15 supplemented PBMC cultures**

PBMCs were resuspended in culture medium, consisting of RPMI (Gibco), 10% vol/vol foetal calf serum (FCS; Gibco) and recombinant human IL-7 or IL-15 (R&D systems) at a final concentration of 1ng/ml, with or without the addition of anti-CD3/CD28 coated-beads (1 bead/cell; Dynal, Compiegne, France) as a co-stimulus. Cells were counted at day 3, 5 and 7 and each time recultured at 1x10^6 cells/ml; a final count was made at day 10. Levels of IL-7Rα and IL-15Rα on cells were determined on the starting population and on days 3, 7 and 10 by co-staining as described above.

**Statistical analysis**

Statistical analysis was performed using GraphPad prism software. Data were compared using a Mann-Whitney test and significant differences verified with 95% confidence intervals.
Results

IL-7Rα and IL-15Rα expression on EBV-specific CD8+ T cells

Figure 1 shows data from a typical experiment comparing an IM patient, IM141, studied in the acute phase of disease and again 3 months and 2 years later, with a healthy HLA-B*0801-matched EBV carrier who had no history of IM. Tetramer staining identifies CD8+ T cells reactive to two B*0801-restricted viral epitopes, the lytic epitope RAK (Figure 1A) and the latent epitope FLR (Figure 1B), and reveals degrees of expansion and subsequent contraction of these virus-specific responses that are typical of primary EBV infection. For both epitope-specific populations, IL-7Rα expression was absent in the acute IM bleed but thereafter the proportion of IL-7Rα-positive cells gradually increased towards the levels seen on the corresponding memory populations in the healthy carrier. By contrast, IL-15Rα expression was undetectable on epitope-specific cells in acute IM but remained so in the two later bleeds. This was markedly different from epitope-specific memory cells in the healthy carrier which were largely (>80%) IL-15Rα-positive.

Figure 2 summarises the cumulative results on EBV-specific CD8+ T cells from 8 IM patients followed prospectively from the time of acute infection, from another 15 IM patients studied only in the acute phase of IM, and from 22 IM patients from whom only later bleeds (1 to 14 years post-IM) were available. They are compared with data from 22 healthy EBV carriers, none of whom had any history of symptomatic primary EBV infection. Overall, the phenotype of five EBV lytic and five EBV latent epitopes, restricted through either HLA-A*0201, B*0801 or B*3501 were examined. All were consistently low for IL-7Rα expression in acute IM after which expression slowly increased, eventually reaching the same range as seen in
healthy carriers but only after a period of two or more years. Generally, latent epitope-specific memory populations showed a higher percentage of IL-7Rα-positive cells (median = 89.1%) than lytic epitope-specific memory (median = 67.7%, p = 0.0015). By contrast, IL-15Rα expression remained essentially undetectable on EBV lytic and latent epitope-specific memory in all post-IM patients, whereas expression was high (medians of 93.9% and 94.5% respectively, p < 0.0001) on the equivalent memory cells in healthy carriers.

**IL-7Rα and IL-15Rα expression on PBMC cell subsets**

We noted from Figure 1 that the absence of IL-15Rα post-IM was not limited to the EBV-specific CD8 response but appeared to affect the whole CD8+ T cell population. Figure 3A shows IL-7Rα and IL-15Rα staining for the total peripheral blood lymphocyte population of patient IM141 at three different time points, again compared to a healthy EBV carrier control. In the acute IM sample, most (75%) of the expanded CD8+ T cell population was IL-7Rα-negative. However, after the resolution of symptoms and the return to a normal CD4/CD8 ratio in the blood, the total CD8+ T cell pool had recovered IL-7Rα expression; note that the CD8-negative lymphocyte population (mainly CD4+ T cells) remained predominantly IL-7Rα-positive at all times. By contrast the total CD8+ T cell pool, and the majority of cells in the non-CD8+ population, were IL-15Rα-negative both in acute IM and up to 2 years later, quite different from the profile seen in a healthy carrier. Figure 3B summarises the overall results from such experiments. Following IM, IL-7Rα expression on total CD8+ T cells recovers to healthy control donor values within a matter of months whereas post-IM CD8+ T cells remained IL-15Rα-negative at all time points studied up to 14 years after disease. In view of these findings, we
considered the possibility that this IL-15Rα deficit might exist in certain individuals before primary EBV infection and that this could predispose them to IM. However we analysed PBMC samples from 30 healthy EBV-naïve adults and found that all expressed both IL-7Rα and IL-15Rα on the majority of CD8+ T cells (Figure 3B).

To ask whether other pathogens inducing clinically apparent mononucleosis might likewise have long-lasting effects on cytokine receptor expression, we studied four individuals who presented with severe IM-like symptoms and large CD8+ T cell expansions caused by primary CMV infection. As shown in Figure 3C, recovery from acute primary CMV infection was accompanied by rising levels of both IL-7Rα and IL-15Rα on total CD8+ T cells, approaching the levels seen in healthy CMV carriers and in CMV-naïve individuals. In one of these CMV-IM patients we were able to study the CD8 response to a CMV-coded epitope (the B7-restricted lytic epitope TPR from the pp65 protein) in acute phase and at 3 and 12 months later. As shown in Supplemental Figure 1, TPR-specific T cells gradually recovered expression of both cytokine receptors, following the trend seen for receptor expression on CD8+ T cells as a whole. These findings strongly suggest that the long-term deficit in IL-15Rα expression seen following classical IM is not a consequence of CD8+ T cell hyper-expansion per se but is a specific marker of individuals with a history of the EBV-associated disease.

From IL-15Rα staining profiles such as Figure 3A, the lymphocyte pool of post-IM patients contained a small subset of CD8-negative cells that were IL-15Rα+. To identify these cells, we co-stained unfractionated PBMCs for the receptor and for subset markers. Data from two post-IM patients (studied 5 and 14 years after their
acute infection) and from two healthy EBV carriers are shown in Figure 4. The post-
IM patients expressed IL-15R\(\alpha\) on both CD19+ B cells and CD14+ monocytes at
levels equivalent to that seen in healthy carriers, but failed to express IL-15R\(\alpha\) on
CD8+ T cells, CD4+ T cells or CD56+ NK cells. We consistently observed these
differences in assays on PBMCs from 11 post-IM patients versus 9 healthy carriers,
using two different anti-IL-15R\(\alpha\)-specific mAbs.

**Functional CD8+ T cell responses to IL-7 and IL-15 in relation to receptor status**

To determine whether cytokine receptor expression levels correlated with
responsiveness, we exposed PBMCs from post-IM patients and healthy virus carriers
to 1ng/ml IL-7 or IL-15 and then assayed for cytokine-triggered phosphorylation of
STAT5 as a marker of response. Figure 5 shows data from a representative IM
patient, the HLA-A*0201-positive IM81, studied in acute phase and 14 years post-
infection, and from a HLA-B*0801-positive EBV carrier control. Responses to IL-7
among CD8+ T cells (Figure 5A) were barely detectable in the acute IM81.1 sample,
whether focusing on cells specific for EBV lytic (YVL) or latent (CLG) epitopes or
on the total CD8 population. However, in the IM81.5 sample taken 14 years later, the
majority of cells in both epitope-specific memory populations and in the CD8
population as a whole showed STAT5 phosphorylation at levels indistinguishable
from the healthy carrier. Importantly, parallel assays using IL-15 as the stimulus
(Figure 5B) clearly showed that the absence of IL-15R\(\alpha\) staining on acute IM and
post-IM T cells was reflected in the lack of a detectable response to the cytokine,
whereas responses were clearly observed in cells of the healthy carrier. These
differences in IL-15 responsiveness were consistently observed in assays comparing 5
acute IM and 8 post-IM donors with 14 healthy EBV carriers.
Figure 6 summarises data from further experiments comparing responses (in 11 long-term post-IM patients versus 18 healthy carrier controls) to increasing cytokine concentrations, mean levels of response being expressed in each case as the percentage of cells showing STAT5 phosphorylation in EBV epitope-specific and in total CD8+ T cell populations. Responses to IL-7 (Figure 6A) titrated similarly in the two types of donor, with responses just detectable at 0.01 ng/ml IL-7 and peaking at 10-100 ng/ml; the only discernable difference was that the maximal response in the total CD8 T cell population was consistently lower in post-IM patients than in healthy carriers. However responses to IL-15 were quite different (Figure 6B): while healthy carriers gave titration curves similar to those seen for IL-7, with significant levels of STAT5 phosphorylation detectable at 0.1 ng/ml IL-15 and almost maximal levels at 10 ng/ml, the post-IM donors only began to show some responses at 10 ng/ml or above. From these titration curves, estimates of cytokine doses required for half-maximal responses showed that post-IM donor CD8+ T cells (whether the EBV-specific or the total population) were > 20-fold less sensitive to IL-15 than healthy carrier cells. This is consistent with IL-15Rα-negative post-IM CD8+ T cells binding cytokine via the low affinity β/γ complex of the IL-15R. Indeed we confirmed by specific mAb staining that CD8+ T cells from post-IM donors did express both β and γ chains at levels in the same range as CD8+ T cells from healthy carriers (data not shown).

Note that these above assays were conducted on whole PBMC populations that contain monocytes. This was a potential concern since, in mouse systems, monocytes have been shown to bind IL-15 through their expression of the IL-15Rα chain and
trans-present the cytokine to CD8+ T cells via the low affinity βγ receptor on the T cell surface 10,20-23. We therefore repeated the above titrations using both monocyte-depleted PBMCs and purified CD8+ T cells as responder populations. As shown in Figure 6C, the clear differential between post-IM and healthy carrier responses was maintained whether or not accessory cells were present. These findings strongly suggest that, in this in vitro system, responses are being induced by direct IL-15 engagement of CD8+ T cells and that the impaired responsiveness of post-IM CD8+ T cells is a direct consequence of IL-15Rα down-regulation on these cells.

Finally, we studied the in vitro proliferative response to 1ng/ml IL-7 and IL-15, comparing PBMCs from long-term post-IM patients with those from healthy carriers, in each case with or without anti-CD3/CD28 mAb-coated beads as a stimulus. As shown in Figure 7A, there was a detectable proliferative response to IL-7 in post-IM PBMC cultures, with or without CD3/CD28 co-stimulation, although this was reproducibly less than that observed in healthy carriers (Figure 7A). However, while PBMCs from healthy carriers maintained cell numbers when cultured in IL-15 alone and proliferated well in co-stimulated cultures, in both situations post-IM PBMCs showed significant levels of cell death within the first 3 days; thereafter there was some proliferation in co-stimulated cultures but progressive death in IL-15 alone (Figure 7B). In the same experiments, we monitored cytokine receptor expression at the beginning of cell culture and in viable cells harvested 3 and 10 days after CD3/CD28 co-stimulation in the presence of cytokine. As shown in Supplemental Figure 2A, in both post-IM and healthy carrier cultures, expression of IL-7Rα was rapidly down-regulated on CD8-positive and on CD8-negative lymphocyte populations by day 3, but then recovered to reach high levels by day 10; at that time,
the majority of cells in the cultures were in fact CD8+ T cells. In the IL-15 and CD3/CD28 co-stimulated cultures the healthy carrier showed a similar response, with down-regulation of IL-15Rα expression by day 3 followed by recovery at day 10. However, even after such combined cytokine and CD3/CD28 co-stimulation, there was never any induction of IL-15Rα on cells from post-IM donors (Supplemental Figure 2B).
Discussion

Prompted by studies showing a role for IL-7 and IL-15 in the development and maintenance of CD8+ memory T cells to viral infection in mouse systems \(^{4,24}\), the present work explored the analogous situation in man by following young adults in whom primary EBV infection is manifest as IM. With regard to IL-7, as for the primary responses in mice \(^{11}\), most of the highly expanded CD8+ T cell population seen in the blood of acute IM patients, including defined EBV epitope-specific populations, have down-regulated IL-7R\(\alpha\) expression. Thereafter, IL-7R\(\alpha\) expression on the total CD8 population recovered to healthy control donor levels within a few months, by which time activated cells have disappeared from the blood and the circulating CD8+ T cell pool has returned within the normal range\(^{25,15}\). Interestingly, EBV epitope-specific CD8+ T cells in the blood of post–IM patients take 2 or more years to acquire the levels of IL-7R\(\alpha\) expression shown by equivalent memory populations in healthy EBV carriers. This contrasts with the situation in mice that have controlled and cleared lymphocytic choriomeningitis virus (LCMV) infection, where IL-7R\(\alpha\) up-regulation appears to be an immediate identifier of cells entering memory \(^{4,11,13}\). The data from post-IM patients are in fact closer to those reported for mice carrying persistent low grade LCMV infection, where virus-specific CD8+ T cells express only low levels of IL-7R\(\alpha\) and appear to be dependent upon continual antigenic stimulation rather than upon IL-7-mediated homeostatic signals for their maintenance \(^{26}\).

Parallels with mouse models broke down when the study turned to IL-15R\(\alpha\) expression. Firstly, while mouse CD8+ T cells are reported to increase IL-15R\(\alpha\) levels in response to antigen stimulation \(^{4,10}\), we found that IL-15R\(\alpha\) was down-
regulated on all activated CD8+ T cells that dominate the blood picture in acute IM, including identifiable EBV epitope-specific populations. Secondly, and most surprisingly, IL-15Rα remained undetectable on CD8+ T cells (again including EBV-specific T cells), on CD4+ T cells and on CD56+ NK cells long after recovery from acute IM. This global deficit in IL-15Rα expression was a defining characteristic of all 22 post-IM patients studied up to 14 years post-infection. By contrast, 22 healthy EBV carriers who had no history of IM (but were age-matched with the IM cohort) always showed IL-15-Rα staining on circulating T and NK cell populations. Although there is no evidence for any familial predisposition to acute IM (except in the special case of SAP gene mutation 27), the data forced us to consider the possibility that an IL-15Rα deficit pre-existed in a subset of EBV-naïve adults and that this was associated with a unique susceptibility to symptomatic primary infection. Unfortunately we could not trace any IM patients from whom PBMCs had been stored before their disease episode. As an alternative, we screened a total of 30 EBV-naïve donors (most of whom were young adults) and found that all expressed IL-15Rα on T cells. Since 25-50% of individuals contracting primary EBV infection as adults are reported to develop IM symptoms28,29, any deficit pre-disposing to IM should have been seen in some members of this cohort. The results strongly suggest that IL-15Rα down-regulation is a consequence (not a precondition) of EBV-associated IM. We then asked whether the effect extended to patients with a clinical history of mononucleosis, associated with large CD8+ T cell expansions, caused by primary CMV infection. While IL-15Rα (and to a lesser extent IL-7Rα) was down-regulated in acute CMV-IM, there was clearly a recovery of receptor expression on total and on CMV-specific CD8+ T cells over the ensuing 12 months. Thus, hyper-
expansion of the CD8+ T cell pool is itself not sufficient to explain the post-EBV-IM phenotype.

These findings raised the possibility that transient down-regulation of IL-15Rα (and to a lesser extent IL-7Rα) expression on CD8+ T cells might be a general feature of acute virus infections in man. In support of this, we recently studied two cases of flu-like respiratory tract infection that occurred among our healthy EBV carrier cohort and were associated with transient CD8+ T cell expansions reaching 38% and 41% of the total PBMC population. These individuals indeed showed down-regulation of IL-15Rα expression on all circulating CD8+ T cells at the height of disease, yet within two weeks of the resolution of symptoms IL-15Rα levels had recovered to those seen before symptoms arose. Expression of IL-7Rα was also reduced during the disease episode and reappeared within one week of clinical recovery (DS and ML, unpublished results). We infer that such global down-regulation of both receptors might be part of an innate physiologic response to acute viral infection, perhaps induced by one or more cytokines produced during such infection. In considering what advantage such a response might bring, it is worth noting that the main effects of IL-7 and IL-15 appear to be in relation to T cell homeostasis rather than in the regulation of antigen-driven T cell activation per se. Indeed combinations of IL-7 and IL-15 are reported to have global effects on human CD8+ T cells in vitro, driving CCR7+, CD45RO+ central memory cells to acquire CCR7-, CD45RO+ effector memory or CCR7-, CD45RA+ effector phenotypes. This has been proposed as a mechanism in vivo for slow antigen-independent replenishment of effector cell populations from the central memory pool. Transient down-regulation of the IL-7 and IL-15 receptors on T cells during an acute viral infection might
therefore guard against the central memory repertoire being depleted of reactivities irrelevant to the immediate viral challenge.

Acute primary EBV-infection, when manifest as IM, appears to be unique in producing a global down-regulation of IL-15Rα on T cells and NK cells that lasts for many years after the disease episode. Whether this long-term receptor deficit has any functional consequences for IL-15 responsiveness became a key question. Thus in mouse systems there is very strong evidence that IL-15Rα status is not the major determinant of a CD8+ T cell’s ability to respond to IL-15. Rather, monocytes are able to capture IL-15 on their surface through expression of IL-15Rα chain and trans-present the cytokine to CD8+ T cells via the latter’s low affinity IL-15Rβ/γ complex. We therefore compared the cytokine responsiveness of post-IM and healthy carrier CD8+ T cells by assaying IL-15-induced STAT5 phosphorylation in vitro in the presence and absence of accessory cells. In both situations, post-IM donors were markedly impaired in their response. This functional defect correlated with the absence of IL-15Rα on post-IM T cells and not with other components of the IL-15R since expression of the IL-15Rβ and γ chains was equivalent in post-IM and healthy carrier cohorts. Such findings imply that, in humans, IL-15Rα status may be a more important determinant of CD8+ T cell sensitivity to IL-15 than it is in mice. We infer that, at least in our in vitro system, trans-presentation by accessory cells is not the principal pathway of IL-15 acquisition by human CD8+ T cells.

These in vitro studies leave open the question as to what the biological consequences of IL-15Rα down-regulation might be in vivo. Ostensibly post-IM patients maintain EBV-specific CD8+ T cell numbers in the memory pool without those cells
expressing the high affinity IL-15Rα. This could be due to compensatory effects mediated by other cytokines or it could reflect a situation like that seen in mice carrying the murine γ-herpesvirus MHV68, where the persistence of virus-specific memory appears to be dependent not upon cytokine signalling but upon chronic antigenic stimulation from the virus \(^3\). We would also stress that, while EBV-specific T cells are present in IM and post-IM patients, we do not know how biologically effective such responses are. Thus IM itself can be a protracted disease with recurrent symptoms in severe cases \(^3\); even in uncomplicated cases the EBV-host balance remains abnormal for long periods after disease resolution \(^3\) and may never reach that typically struck after asymptomatic primary infection. Furthermore recent epidemiological evidence has shown that post-IM patients remain at significantly increased risk of an EBV-positive malignancy, Hodgkin’s lymphoma, for at least 10 years after their original disease episode \(^4\). Given the widespread nature of the IL-15Rα down-regulation on T and NK cells, and the possibility that some non-haemopoietic cell lineages \(^4\) could also be affected, a history of IM may carry with it other disease risks which have not yet been recognised. These longer-term issues remain to be resolved. More immediately, the present work shows that symptomatic primary EBV infection leaves a long-lasting scar on the immune system. As a result, post-IM patients represent a potentially unique cohort of individuals through which to analyse the effects of impaired IL-15 signalling not just on human T cell and NK cell functions \textit{in vitro} but also on the homeostatic turnover of these cell populations \textit{in vivo} \(^4\).
Acknowledgements

We are very grateful to Dr Naeem Khan (Birmingham) for providing CMV-restricted tetramers, to Dr Mark Wills (Cambridge) for access to PBMCs from post-CMV IM patients, and to Drs Dorothy Crawford (Edinburgh), Jan Gratama (Rotterdam), Eric Robinet (Besancon), Cliona Rooney (Houston) and Tim Wellinger (Oxford) for providing PBMCs from EBV- naïve donors.
References


Figure Legend

**Fig.1: IL-7Rα and IL-15Rα expression on EBV-specific CD8+ T cells.**

Representative staining profiles are shown for CD8+ T cells specific for (A) the HLA-B*0801-restricted EBV lytic cycle epitope RAK and (B) for the HLA-B*0801-restricted EBV latent cycle epitope, FLR.

Left hand panels: FACS profiles of tetramer vs CD8 staining among PBMCs; percentage values refer to the percentage of tetramer-positive cells in the CD8+ population. Middle and right hand panels: FACS profiles of tetramer vs IL-7Rα and tetramer vs IL-15Rα staining among CD8+ T cells respectively; percentage values refer to the percentage of IL-Rα positive cells within the tetramer-positive population.

Panels running top to bottom show the profiles obtained from one HLA-B*0801-positive patient, IM141, studied in acute phase (IM141.1), 3 months later (IM141.2), and 2 years later (IM141.5), all stained in the same experiment alongside cells from a HLA-B*0801-positive healthy EBV carrier with no history of IM.

**Fig.2: Summary of IL-7Rα and IL-15Rα expression on EBV-specific CD8+ T cells in acute IM and post-IM patients versus healthy carriers.**

Scatter plots of IL-7Rα expression (left) or IL-15Rα (right) on EBV lytic epitope-specific CD8+ T cells (upper panels) and on EBV latent epitope-specific CD8+ T cells (lower panels). Results are expressed as the percentage of tetramer-positive cells that are IL-7Rα or IL-15Rα positive, respectively and each individual symbol shows the value for a particular epitope in a particular donor tested within a particular time interval post-infection, i.e. in acute IM, 1-18 months post-IM, and 2-14 years post-IM. Results for equivalent EBV epitope-specific memory cells in healthy EBV carriers are
also shown (grey area). Horizontal lines represent the median value for each specificity/time point combination. Statistical analysis was performed using Mann-Whitney test; significant differences are indicated by asterisks (* p<0.001; ** p<0.0001).

**Fig.3: IL-7Rα and IL-15Rα expression on total lymphocyte populations.**

A. Representative staining profiles for IL-7Rα expression (left) and IL-15Rα expression (right) on PBMCs co-stained with anti-CD8 mAb. Analysis was restricted to the lymphocyte population (i.e. excluding monocytes) by gating on cell size. These results involve the same IM donor, studied in acute phase, 3 months and 2 years later, and the same healthy EBV carrier as in Figures 1 and 2. Percentage values refer to the percentage of IL-R positive cells among the CD8+ population.

B, C. Scatter plots summarising IL-7Rα expression (left panel) and IL-15Rα expression (right panel) on total CD8+ T cells during and at intervals after EBV-associated IM (B) or CMV-associated IM (C). In all plots, results are expressed as the percentage of CD8+ cells that are IL-7Rα or IL-15Rα positive. Each symbol shows the value for a particular donor within a particular time interval post-infection. Cumulative results from IL-R stainings carried out on the CD8+ T cells of 22 healthy EBV-carriers with no history of EBV-IM (light grey shading) and 30 healthy EBV-naïve individuals (dark grey shading) are shown in the upper panels; similarly, results from 10 healthy CMV-carriers and 5 healthy CMV-naïve individuals are shown in the lower panels. Horizontal lines represent the median value in each case. Statistical analysis was performed using Mann-Whitney test; significant differences are indicated by asterisks (* p<0.001; ** p<0.0001).
Fig.4: Expression of IL-15Rα on different PBMC cell subsets.

Histograms of IL-15Rα staining are shown for two long term post-IM patients studied 5 and 14 years post-infection (left panel) and for two healthy EBV carriers (right panel); in each case PBMCs were co-stained with IL-15Rα mAb and with cell subset-specific markers. Panels running top to bottom show IL-15Rα staining profiles on gated populations of CD8+ T cells, CD4+ T cells, CD56+ NK cells, CD19+ B lymphocytes and CD14+ monocytes. The shaded histograms represent staining of the same gated population with a mouse isotype control. These results are representative of those obtained in experiments on 11 post-IM patients and 9 healthy carriers.

Fig.5: Cytokine-induced STAT5 phosphorylation in CD8+ populations.

Representative example of STAT5 phosphorylation induced after stimulation of PBMCs with (A) 1 ng/ml IL-7 or (B) 1 ng/ml IL-15. Results are shown for the HLA-A*0201-positive patient IM81 studied in the acute disease (IM81.1) and 14 years later (IM81.5), and for an HLA-B*0801-positive healthy carrier. In each case, STAT5 phosphorylation is analysed on EBV lytic epitope-specific populations (against the HLA-A*0201-restricted YVL and HLA-B*0801-restricted RAK epitopes respectively) and EBV latent epitope-specific populations (against the HLA-A*0201-restricted CLG and HLA-B*0801-restricted FLR epitopes respectively). Percentage values in the upper right quadrant of each dot plot refer to the percentage of STAT5 phosphorylation in tetramer-positive cells, whereas values in the lower right quadrant indicate the percentage of STAT5 phosphorylation in the total CD8+ population. Quadrant boundaries were set using non-stimulated cells from the same donors.
Fig. 6: Titration of STAT5 phosphorylation response to IL-7 and IL-15.

A, B. Mean results from 11 post-IM patients (closed symbols) and 18 healthy carriers (open symbols) in experiments assaying cytokine-induced STAT5 phosphorylation after exposure to the indicated doses of (A) IL-7 or (B) IL-15. Results are expressed as the percentage of EBV tetramer-positive cells (left panels) or total CD8+ cells (right panels) showing STAT5 phosphorylation. Data on EBV-specific populations represent cumulative results obtained with four tetramers all specific for EBV lytic cycle epitopes; similar results were obtained with five latent epitope-specific tetramers. C. STAT5 phosphorylation in assays conducted on purified CD8+ populations (left panel) and on CD14-depleted PBMC populations (right panel). Representative results are shown from one of 5 experiments comparing post-IM patient and healthy carrier responses to the indicated doses of IL-15; results are expressed as the percentage of total CD8+ T cells showing STAT5 phosphorylation.

Fig. 7: Cell numbers in IL-7 and IL-15 supplemented PBMC cultures

Mean results from 8 post-IM patients and 6 healthy EBV carriers in experiments where PBMCs were seeded in culture at 1x10^6/ml in the presence of (A) IL-7 or (B) IL-15 at 1ng/ml, with or without anti-CD3/CD28 coated-beads as a co-stimulus. Cell counts were performed on day 3, 5, 7 and 10 and viable cell numbers are expressed relative to the initial seeding.
Figure 1
Figure 2
Figure 3
Figure 4
Figure 5
Figure 6
A. IL-7

B. IL-15

Figure 7
EBV-associated mononucleosis leads to long-term global deficit in T cell responsiveness to IL-15

Delphine Sauce, Martin Larsen, S John Curnow, Alison M Leese, Paul A Moss, Andrew D Hislop, Michael Salmon and Alan B Rickinson